课题基金 / 基金详情

NOVEL DNA DOUBLE STRAND BREAK REPAIR TARGETING THERAPEUTICS FOR CANCER TREATMENT

NOVEL DNA DOUBLE STRAND BREAK REPAIR TARGETING THERAPEUTICS FOR CANCER TREATMENT
新型 DNA 双链断裂修复靶向治疗癌症
批准号:
8827725
负责人:
LARRY A. SKLAR
金额:
$36.12万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-04-01 至 2015-08-31

项目摘要

项目成果

LARRY A. SKLAR的其他基金

相似基金

相关文献

中文摘要
翻译
描述:癌细胞经常使DNA双链断裂(DSB)修复蛋白失活,导致基因组不稳定和肿瘤的遗传进化。由于代偿性修复途径的活性,这些蛋白质的失活通常不会引起DNA DSB修复的明显缺陷。我们认为,确定削弱这些代偿途径的化合物将是开发治疗药物的第一步,这些药物可以使肿瘤细胞敏感,而不是正常组织对基因毒性癌症治疗敏感。DNA损伤反应组蛋白H2AX是一种剂量依赖性肿瘤抑制因子,在许多癌症中表现出表达减少。H2AX缺乏会导致基因组不稳定,但不会导致非同源末端连接(NHEJ)修复DNA DSB的明显缺陷。NHEJ因子XLF的缺乏也不会导致NHEJ的明显缺陷。然而,H2AX和XLF的联合缺乏导致NHEJ对DSB的修复严重受阻。这些发现表明,H2AX和XLF参与代偿性DSB修复通路,在缺乏另一条通路的细胞中抑制一条通路将导致NHEJ的严重阻断。我们与新墨西哥大学分子发现中心(UNMCMD)合作,开发了一种流式细胞术高通量筛选抑制NHEJ的化合物。该筛选已被优化,并用于筛选一个小的化合物库(1500),达到了>.6的Z′分数。在这里,我们建议使用这种方法筛选更大、更复杂的化学文库,以鉴定在h2ax缺陷细胞中特异性抑制NHEJ的化合物,而不是野生型细胞。我们将这些化合物称为h2ax特异性NHEJ合成抑制剂(SINs)。一个线性的,多步骤的方法来验证这些化合物的功能也将被开发。我们相信,开发出选择性抑制癌细胞中NHEJ的药物,最终将使我们能够利用DNA修复途径缺陷来治疗癌症。此外,与目前选择性抑制DSB修复的其他主要途径——癌细胞中的同源重组(homologous recombination, HR)相比,这种方法具有显著的优势。虽然HR仅在分裂细胞中修复DSB,但在细胞周期的G0-G1期,所有细胞都需要NHEJ来修复DSB。因此,我们通过筛选确定的抑制NHEJ的药物将有效治疗所有癌细胞,包括绝大多数不活跃分裂的癌细胞。重要的是,癌症干细胞被认为是许多癌症治疗后复发的基础,主要存在于G1期,也会被SINs致敏。除了鉴定h2ax特异性的SINs外,这些研究的完成将为未来鉴定用于治疗多种DNA DSB修复蛋白缺陷的癌症的SINs建立一个线性管道。此外,他们还将识别正常细胞和癌细胞使用的新的DSB修复途径。
英文摘要
DESCRIPTION: Cancer cells frequently inactivate DNA double strand break (DSB) repair proteins causing genomic instability and the genetic evolution of tumors. Inactivation of these proteins usually does not cause overt defects in DNA DSB repair due to the activity of compensatory repair pathways. We reason that identifying compounds that cripple these compensatory pathways will be the first step in developing therapeutic agents that can sensitize tumor cells, but not normal tissues to genotoxic cancer therapies. The DNA damage response histone protein H2AX is a dosage-dependent tumor suppressor that exhibits reduced expression in many cancers. H2AX deficiency leads to genomic instability, but not to overt defects in DNA DSB repair by non-homologous end joining (NHEJ). Deficiency in the NHEJ factor XLF also does not lead to demonstrable defects in NHEJ. However, the combined deficiency of H2AX and XLF leads to a severe block in DSB repair by NHEJ. These findings demonstrate that H2AX and XLF are in compensatory DSB repair pathways and that inhibition of one pathway in cells deficient in the other will lead to a profound block in NHEJ. In conjunction with the University of New Mexico Center for Molecular Discover (UNMCMD), we have developed a flow cytometric high throughput screen for chemical compounds that inhibit NHEJ. This screen has been optimized and used to screen a small library of compounds (1,500) achieving Z' scores of >0.6. Here, we propose to use this approach to screen a larger, more complex chemical library to identify compounds that inhibit NHEJ specifically in H2AX-deficient, but not wild type cells. We refer to these compounds as H2AX-specific Synthetic Inhibitors of NHEJ (SINs). A linear, multistep approach to validate the function of these compounds will also be developed. We believe that developing agents that selectively inhibit NHEJ in cancer cells will ultimately enable us to exploit DNA repair pathway defects to treat cancers. Moreover, this approach has significant advantages over current efforts to selectively inhibit the other major pathway of DSB repair, homologous recombination (HR) in cancer cells. Whereas HR only functions in DSB repair in dividing cells, NHEJ is required for DSB repair in all cells in the G0-G1 phases of the cell cycle. Thus, agents identified by our screen, which inhibit NHEJ will be effective in treating all cancer cells including the vast majority that are not actively dividing. Importantly, cancer stem cells, which are thought to be the basis for relapse of many cancers after treatment, exist primarily in G1 and would also be sensitized by SINs. In addition to identifying H2AX-specific SINs, completion of these studies will establish a linear pipeline for th future identification of SINs for treating cancers defective in a broad range of DNA DSB repair proteins. Moreover, they will also identify novel DSB repair pathways used by normal cells and cancer cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Autophagy Scientific Core
Illuminating the Druggable Genome Resource Dissemination and Outreach Center (IDG-RDOC)
Illuminating the Druggable Genome Resource Dissemination and Outreach Center (IDG-RDOC)
NOVEL DNA DOUBLE STRAND BREAK REPAIR TARGETING THERAPEUTICS FOR CANCER TREATMENT
  • 批准号:
    8693254
  • 项目类别:
  • 资助金额:
    $46.26万
  • 财政年份:
    2014
  • 负责人:
    LARRY A. SKLAR
  • 依托单位:
海外基金